Close

Have A Question?


Connect with Camargo today.

Contact Us
Blog & Resources Camargo Blog Market & Commercialization

The Camargo Blog

Get insight and information from our team of experts to improve your pharmaceutical development and commercialization strategy.


November 8th, 2018

Market Assessment:

May 17th, 2017

Due Diligence Assessment: Determining a Drug Product’s Potential Value

January 27th, 2016

3-Year Exclusivity May Not Be Worth as Much as You Think

June 2nd, 2015

Pediatrics—What are the appropriate age ranges?

March 29th, 2015

PhRMA and GPhA Team Up (!) to Offer their EAR Proposal to Solve Generic Safety Labeling Issue

January 17th, 2015

FDA 2014 NDA Approvals—The Surge of the Niche Products—Good or Bad?

September 22nd, 2014

Paper Submissions: Going, Going… Away

July 22nd, 2014

MannKind Breathes Easier—Inhaled Insulin Finally Approved

June 30th, 2014

Importing Pre-Launch Products with a Bit of PLAIR

April 8th, 2014

The Road to Commercial Success—The Target Product Profile

July 1st, 2013

FDA Goes Against Advisory Committee and Approves Low Dose Paroxentine for Hot Flashes

March 25th, 2013

Are 505(b)(2)’s “Super Generics” or What Do We Call Them?

February 11th, 2013

No 5-Year Exclusivity for Combinations Drugs with an NCE

April 19th, 2012

ViroPharma Denied Request for 3-year Exclusivity

April 12th, 2012

NIH Head Urges Repositioning/Repurposing

October 3rd, 2011

Don’t Launch Unapproved Products After 9/19/2011

June 24th, 2011

Whew! Supreme Court Rules Generic Labels Must Track RLD

June 2nd, 2011

Why Generic Companies Might Like 505(b)(2)

May 31st, 2011

K-V’s Makena: Part 3: Use of Public Information for 505(b)(2) Approvals

May 18th, 2011

K-V’s Makena® Part 1: 505(b)(1) or 505(b)2)?

January 6th, 2011

2010 505(b)(2) Approvals

August 23rd, 2010

Lannett’s Morphine Sulfate Oral Solution: 505(b)(2) or 505j?

August 23rd, 2010

Will We Have Generic User Fees? Public Meeting to Be Held.

August 4th, 2010

New User Fees for 2011

Page 1 of 3


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights